ECMO in severe hypoxemia post liver transplant for hepatopulmonary syndrome

Jesús Emilio Barrueco-Francioni,María Carmen Martínez-González,Juan Francisco Martínez-Carmona,María Palma Benítez-Moreno,Cesar Aragón-González,Manuel Enrique Herrera-Gutiérrez
DOI: https://doi.org/10.1177/03913988241274252
2024-09-03
The International Journal of Artificial Organs
Abstract:The International Journal of Artificial Organs, Ahead of Print. Hepatopulmonary syndrome (HPS) poses a significant challenge in liver transplant patients, affecting between 10% and 30% of candidates. Historically, HPS was considered a contraindication for liver transplantation due to its association with high mortality rates. However, recent studies have shown improvements in pulmonary function post-transplant, leading to the inclusion of these patients as candidates. Despite this progress, approximately one-fifth of liver transplant recipients develop severe postoperative hypoxia, further complicating their clinical course and contributing to increased mortality. The management of post-transplant HPS involves various strategies, including extracorporeal membrane oxygenation (ECMO), although its use remains infrequently reported. Theoretical models suggest that oxygenation typically improves within 10 days post-transplant, while resolution of HPS may take 6–12 months, making ECMO an attractive possibility as a bridge to recovery in this population. We present a case were ECMO was used in this context.
engineering, biomedical,transplantation
What problem does this paper attempt to address?